Although validation in larger cohorts is required to confirm our results, our proposed prognostic marker for adenocarcinoma, pERK, shows an independent prognostic potential with a hazard ratio of approximately 4 in progression-free and overall survival. This evidence concerns the gene EIF2AK3 and adenocarcinoma.